KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Vir Biotechnology (VIR) over the last 8 years, with Q3 2025 value amounting to -$262000.0.

  • Vir Biotechnology's Gains from Investment Securities rose 7681.42% to -$262000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.5 million, marking a year-over-year increase of 5892.69%. This contributed to the annual value of $5.5 million for FY2024, which is 7474.42% down from last year.
  • Per Vir Biotechnology's latest filing, its Gains from Investment Securities stood at -$262000.0 for Q3 2025, which was up 7681.42% from $14.0 million recorded in Q2 2025.
  • Over the past 5 years, Vir Biotechnology's Gains from Investment Securities peaked at $95.0 million during Q1 2022, and registered a low of -$372.0 million during Q4 2022.
  • For the 5-year period, Vir Biotechnology's Gains from Investment Securities averaged around -$18.7 million, with its median value being $1.2 million (2024).
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 183588.9% in 2021, then soared by 15318870.97% in 2022.
  • Vir Biotechnology's Gains from Investment Securities (Quarter) stood at $26.0 million in 2021, then crashed by 1529.69% to -$372.0 million in 2022, then surged by 100.27% to $993000.0 in 2023, then grew by 18.03% to $1.2 million in 2024, then plummeted by 122.35% to -$262000.0 in 2025.
  • Its Gains from Investment Securities was -$262000.0 in Q3 2025, compared to $14.0 million in Q2 2025 and -$6.4 million in Q1 2025.